Total de visites
| Visites | |
|---|---|
| Immuno-priming ... | 64 |
Total de visites per mes
| d’octubre 2023 | de novembre 2023 | de desembre 2023 | de gener 2024 | de febrer 2024 | de març 2024 | d’abril 2024 | |
|---|---|---|---|---|---|---|---|
| Immuno-priming ... | 0 | 3 | 0 | 1 | 0 | 1 | 3 |
Total de descàrregues del fitxer
| Visites | |
|---|---|
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura5.pdf | 15 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura2.pdf | 15 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020.pdf | 15 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura4.pdf | 13 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_taula1.pdf | 12 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura1.pdf | 11 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura3.pdf | 10 |
Visites per país
| Visites | |
|---|---|
| Estats Units | 45 |
| Espanya | 7 |
| Alemanya | 3 |
| Suècia | 3 |
| França | 2 |
| Finlàndia | 1 |
| Irlanda | 1 |
| Rússia | 1 |
| Eslovènia | 1 |
Visites per ciutat
| Visites | |
|---|---|
| Chandler | 10 |
| Ashburn | 9 |
| Chicago | 8 |
| Barcelona | 4 |
| Boardman | 3 |
| Phoenix | 3 |
| Columbus | 1 |
| Des Moines | 1 |
| Dublin | 1 |
| Helsinki | 1 |